Enzymatic peptide cross-linking to make unstable peptides drug-like — platform bet, very early.
Sethera Therapeutics
venture active confidence: Low status: Draft updated 2026-07-14
Summary
Sethera Therapeutics is developing enzymatically cross-linked peptides designed to reach disease targets that small molecules miss. The platform could speed later drugs if the chemistry generalizes, but without a clinical candidate its impact remains a local, early-stage bet.
Impact
GLP-1 agonists demonstrated that stabilized peptides can become blockbuster medicines. If Sethera's enzymatic approach generalizes, it could open intracellular and PPI targets currently considered undruggable. Impact is entirely conditional on platform generalization — the first drug is the hard one; subsequent candidates would be faster if chemistry holds.
What They Are Building
The pMCP Discovery Platform lets partners discover and engineer macrocyclic peptides with diverse architectures. The cyclization enzyme recognizes programmable sequence motifs to install thioether bonds, potentially multiple times per molecule. Sethera is actively seeking collaboration partners for target screening and drug-discovery programs.
What They Need Now
Likely needs include peptide chemists, enzymologists, medicinal chemists, in-vivo pharmacologists, and platform-partnership business development. Very early team; broad roles and high individual leverage typical of academic spinouts.
Who Could Help
Useful helpers include U of U technology-transfer connectors, peptide-platform pharma partners, GMP peptide-synthesis operators, and early biotech investors comfortable with 8–15 year platform timelines.
Utah Context
Sethera is a U of U research spinout at 48 S Rio Grande Street in Salt Lake City, alongside Utah's peptide-and-biologics cluster (Recursion Pharmaceuticals, 3Helix, CaLycia Biosciences).
Evidence
Open Questions
- Does enzymatic stabilization generalize across peptide targets with preserved affinity, acceptable pharmacokinetics, and no new immunogenicity?
- Clinical-candidate timeline and lead-program disclosure — no IND or clinical program appears in any source captured here.
- How does the platform compare with stapled peptides, macrocyclization companies, ADCs, and other peptide-stabilization approaches?
- Funding stage and team size beyond the official team page — nothing captured here names a round, an amount, or a headcount.
- Platform biotech plays typically need 8–15 years from founding to first approved drug; Sethera was founded ~2023.
- No agent-readable careers/jobs page found (setheratx.com/careers 404).